Detected ·
Nouscom
€120MSeries D
Nouscom raised an oversubscribed €120M ($135M) Series D co-led by M Ventures and Revelation Partners, with new investors Angelini Industries, the European Investment Bank (EIB) and NEVA SGR, to advance its off-the-shelf cancer interception immunotherapy NOUS-209 into a global pivotal trial for Lynch syndrome.
- Website
- —
- linkedin.com/company/18328527
- Amount
- €120 000 000 EUR
- Stage
- Series D
- Event
- Funding round
- Detected
- 2026-10-20 12:07:15 UTC
- Signal ID
- 08179c6a-6ddb-41c6-b9b4-5cc9465ce343
As the API returns it
{
"id": "08179c6a-6ddb-41c6-b9b4-5cc9465ce343",
"created_at": "2026-10-20T12:07:15.639585Z",
"company_name": "Nouscom",
"company_website_url": null,
"company_linkedin_url": "https://www.linkedin.com/company/18328527",
"event_type": "funding",
"funding_amount": 120000000,
"funding_currency": "EUR",
"funding_stage": "series_d",
"message": "*Nouscom raised an oversubscribed €120M ($135M) Series D co-led by M Ventures and Revelation Partners, with new investors Angelini Industries, the European Investment Bank (EIB) and NEVA SGR, to advance its off-the-shelf cancer interception immunotherapy NOUS-209 into a global pivotal trial for Lynch syndrome.*"
}